Lifevantage (NASDAQ:LFVN) Updates FY 2026 Earnings Guidance

Lifevantage (NASDAQ:LFVN) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 1.000-1.150 for the period, compared to the consensus estimate of 1.030. The company issued revenue guidance of $225.0 million-$240.0 million, compared to the consensus revenue estimate of $232.2 million.

Lifevantage Price Performance

Shares of LFVN stock traded down $0.34 during mid-day trading on Tuesday, hitting $7.00. The stock had a trading volume of 331,180 shares, compared to its average volume of 187,016. The firm has a market cap of $88.84 million, a PE ratio of 9.46 and a beta of 0.26. The company’s 50-day simple moving average is $10.25 and its 200-day simple moving average is $11.90. Lifevantage has a fifty-two week low of $6.97 and a fifty-two week high of $27.38.

Lifevantage (NASDAQ:LFVN) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.01. Lifevantage had a net margin of 4.29% and a return on equity of 33.75%. Lifevantage has set its FY 2026 guidance at 1.000-1.150 EPS.

Lifevantage Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 16th. Shareholders of record on Monday, September 8th were given a dividend of $0.045 per share. The ex-dividend date was Monday, September 8th. This represents a $0.18 annualized dividend and a yield of 2.6%. Lifevantage’s payout ratio is presently 24.32%.

Wall Street Analyst Weigh In

LFVN has been the topic of several recent analyst reports. Weiss Ratings reiterated a “hold (c+)” rating on shares of Lifevantage in a research report on Wednesday, October 8th. Wall Street Zen cut Lifevantage from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $30.50.

Insider Buying and Selling

In other Lifevantage news, Director Michael A. Beindorff sold 4,125 shares of the firm’s stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $11.44, for a total transaction of $47,190.00. Following the completion of the transaction, the director owned 22,858 shares of the company’s stock, valued at approximately $261,495.52. This trade represents a 15.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 21.95% of the company’s stock.

Institutional Trading of Lifevantage

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LFVN. Jane Street Group LLC raised its stake in Lifevantage by 5.4% in the 1st quarter. Jane Street Group LLC now owns 36,567 shares of the company’s stock valued at $533,000 after purchasing an additional 1,877 shares during the last quarter. Cetera Investment Advisers boosted its stake in shares of Lifevantage by 10.8% during the 2nd quarter. Cetera Investment Advisers now owns 20,098 shares of the company’s stock worth $263,000 after purchasing an additional 1,954 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Lifevantage by 870.2% during the second quarter. JPMorgan Chase & Co. now owns 5,016 shares of the company’s stock worth $66,000 after buying an additional 4,499 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of Lifevantage by 19.6% during the second quarter. Bank of America Corp DE now owns 33,376 shares of the company’s stock valued at $437,000 after buying an additional 5,472 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Lifevantage during the second quarter valued at approximately $76,000. Hedge funds and other institutional investors own 35.32% of the company’s stock.

About Lifevantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.